The following is a summary of “Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis,” published in the January 2025 issue of Psychiatry by Fountoulakis et al.

Esketamine is the first monotherapy for MDD with inadequate response to two oral antidepressants, approved after a priority FDA review. Clinical trials showed esketamine's rapid efficacy ...

Before beginning esketamine patient care, it’s vital to determine if they are a suitable candidate for this treatment. This ...

for SPRAVATO ® (esketamine) CIII nasal spray, making this innovative treatment the first and only monotherapy for adults living with major depressive disorder (MDD) who have had an inadequate ...

6 The mechanism by which esketamine exerts its antidepressant effect is unknown. Backed by more than a decade of research and almost six years of real-world evidence, SPRAVATO® has proven to be a ...

Kelsey Warren [email protected]  609 218 4053 Investor contact: Lauren Johnson [email protected] ...

This week, the US Food and Drug Administration expanded its approval of Spravato, an antidepressant nasal spray. The drug, made by Johnson & Johnson, is now cleared for use as the only standalone ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who ...

An application for Janssen’s investigative nasal ketamine-based antidepressant is under review in Europe ... to the European Medicines Agency for esketamine nasal spray, which is designed ...

Manufacturer Janssen says Esketamine can lift a patient's mood within 24 hours of use. The drug is intended for patients who have not responded to two other, conventional antidepressants which can ...

Ketamine, when abused, can be tremendously harmful and addictive. Nevertheless, esketamine, a dissociative hallucinogen that ...

The US Food and Drug Administration (FDA) has approved the use of esketamine nasal spray as a standalone treatment for adults with major depressive disorder (MDD) who have not responded adequately ...